Veracyte, Inc.
VCYT
Ранг среди акций
#4240
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Цена акции
$46.01
Рыночная капитализация
$3.70B
Изменение (1 день)
-0.47%
Изменение (1 год)
32.39%
Страна
US
Торговля Veracyte, Inc. (VCYT)
Категория
Healthcare
История цены акций Veracyte, Inc. (VCYT)
Наивысшая цена закрытия: $44.58 2026-10-01
Наименьшая цена закрытия: $12.82 2013-10-01
Наименьшая цена закрытия: $12.82 2013-10-01
История цены акций Veracyte, Inc. с 2013 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2026 (TTM) | -2.87% |
| 2025 | 3.85% |
| 2024 | 55.02% |
| 2023 | 1.26% |
| 2022 | -33.63% |
| 2021 | -25.42% |
| 2020 | 88.25% |
| 2019 | 137.21% |
| 2018 | 87.23% |
| 2017 | -13.42% |
| 2016 | 5.54% |
| 2015 | -8.13% |
| 2014 | -43.76% |
| 2013 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $676.48 | 19.27% |
US
|
|
| $229.93 | 5.42% |
US
|
|
| $398.85 | 112.13% |
US
|
|
| $21.16 | 49.45% |
CN
|
|
| $174.35 | 19.52% |
US
|
